SCHEMBL25240993

SCHEMBL25240993

O=C(O)c1cnc(F)cc1OC1CC1

nearest known ligand 0.38

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 3/20 0.38
PDE4B Q07343 3/20 0.38
PDE4C Q08493 3/20 0.38
PDE4D Q08499 3/20 0.38
KMO O15229 3/20 0.38
DHODH Q02127 2/20 0.37
KDM4E B2RXH2 1/20 0.37
ASPH Q12797 1/20 0.37
KDM8 Q8N371 1/20 0.37
SCD O00767 3/20 0.35
MKNK1 Q9BUB5 2/20 0.35
MKNK2 Q9HBH9 2/20 0.35
GRIK1 P39086 2/20 0.35
IP6K1 Q92551 2/20 0.35
KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31208526 0.81 DPP4 (0.44) KDM4EKMT2A
SCHEMBL25234713 0.81 DPP4 (0.44) KDM4EKMT2A
SCHEMBL25232405 0.81 GABRP (0.39) PDE4APDE4BPDE4CPDE4DKMO
SCHEMBL29955165 0.79 KMO (0.36) PDE4APDE4BPDE4CPDE4DKMO
SCHEMBL25235667 0.78 KDM4E (0.47) KDM4EASPHKDM8
SCHEMBL31197237 0.74 GRIK1 (0.43) PDE4APDE4BPDE4CPDE4DSCD
SCHEMBL25213581 0.73 FEN1 (0.36) PDE4APDE4BPDE4CPDE4DSCD
SCHEMBL31535212 0.73 TSHR (0.41) PDE4APDE4BPDE4CPDE4DSCD
SCHEMBL23012559 0.73 KMO (0.39) KMOSCDGRIK1KMT2A
SCHEMBL24468017 0.71 KEAP1 (0.47) PDE4APDE4BPDE4CPDE4DSCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12595245-B2 Inhibitors of MET kinase CELYN THERAPEUTICS, INC. (US) 2026-04-07 US disclosed
EP-4448510-A1 INHIBITORS OF MET KINASE Kinnate Biopharma Inc. (US) 2024-10-23 EP disclosed
CN-118742542-A Inhibitors of MET kinase 金耐特生物制药公司 2024-10-01 CN disclosed
US-20240067626-A1 INHIBITORS OF MET KINASE CELYN THERAPEUTICS, INC. 2024-02-29 US disclosed
US-11753395-B2 Inhibitors of MET kinase KINNATE BIOPHARMA INC. (US) 2023-09-12 US disclosed
US-20230219929-A1 INHIBITORS OF MET KINASE CELYN THERAPEUTICS, INC. 2023-07-13 US disclosed
WO-2023114809-A1 INHIBITORS OF MET KINASE KINNATE BIOPHARMA INC. (US) 2023-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12595245-B2 Inhibitors of MET kinase MET, ABL1, ERBB2 PDE4A 1998/4885PDE4B 2032/4885PDE4C 2321/4885
US-20230219929-A1 INHIBITORS OF MET KINASE MET, RET, MERTK PDE4A 3024/4885PDE4B 2859/4885PDE4C 3067/4885
US-11753395-B2 Inhibitors of MET kinase MET, RET, MERTK PDE4A 3024/4885PDE4B 2859/4885PDE4C 3067/4885
US-20240067626-A1 INHIBITORS OF MET KINASE MET, RET, MERTK PDE4A 3024/4885PDE4B 2859/4885PDE4C 3067/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.